Literature DB >> 32887534

Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics.

Christina Großerichter-Wagener1, Dorien Kos2, Astrid van Leeuwen3, Lisanne Dijk1, Jorn Jeremiasse1, Floris C Loeff1, Theo Rispens1.   

Abstract

Antibody formation to human(ized) therapeutic antibodies in humans is highly skewed toward anti-idiotype responses, probably because the idiotype is the only 'foreign' part of the antibody molecule. Here, we analyzed antibody responses to F(ab')2 fragments of a panel of 17 human(ized) therapeutic antibodies in rabbits. Homology between the rabbit germline and the human(ized) antibodies is moderate not only for the variable domains (both the complementarity-determining regions and the framework regions), but also for the constant domains (66% or less). Nevertheless, we observed a highly skewed anti-idiotype response in all cases, with up to >90% of the antibodies directed toward the idiotype. These results indicate that the idiotype may be inherently immunodominant. We used these biased responses to raise monoclonal rabbit anti-idiotype antibodies against secukinumab, ustekinumab, reslizumab, mepolizumab, palivizumab, and dupilumab and demonstrate the potential to develop sensitive pharmacokinetic assays with these antibodies.

Entities:  

Keywords:  PK/ADA assays; anti-idiotype antibodies; rabbit monoclonal antibodies

Year:  2020        PMID: 32887534      PMCID: PMC7531530          DOI: 10.1080/19420862.2020.1814661

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  24 in total

1.  Refocusing of B-cell responses following a single amino acid substitution in an antigen.

Authors:  M D Chiesa; P M Martensen; C Simmons; N Porakishvili; J Justesen; G Dougan; I M Roitt; P J Delves; T Lund
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Production of recombinant Ig molecules from antigen-selected single B cells and restricted usage of Ig-gene segments by anti-D antibodies.

Authors:  Serge E Dohmen; Arend Mulder; Onno J H M Verhagen; Chantal Eijsink; Marry E I Franke-van Dijk; C Ellen van der Schoot
Journal:  J Immunol Methods       Date:  2005-03       Impact factor: 2.303

3.  Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.

Authors:  Karin A van Schie; Simone Kruithof; Pleuni Ooijevaar-de Heer; Ninotska I L Derksen; Fleur S van de Bovenkamp; Anno Saris; Gestur Vidarsson; Arthur E H Bentlage; Wim Jiskoot; Stefan Romeijn; Roman I Koning; Erik Bos; Eva Maria Stork; Carolien A M Koeleman; Manfred Wuhrer; Gertjan Wolbink; Theo Rispens
Journal:  Ann Rheum Dis       Date:  2018-06-26       Impact factor: 19.103

4.  Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Authors:  Theo Rispens; Astrid van Leeuwen; Anke Vennegoor; Joep Killestein; Rob C Aalberse; Gerrit J Wolbink; Lucien A Aarden
Journal:  Anal Biochem       Date:  2011-01-07       Impact factor: 3.365

5.  Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays.

Authors:  Sumin Bian; Thomas Van Stappen; Filip Baert; Griet Compernolle; Els Brouwers; Sophie Tops; Annick de Vries; Theo Rispens; Jeroen Lammertyn; Séverine Vermeire; Ann Gils
Journal:  J Pharm Biomed Anal       Date:  2016-03-15       Impact factor: 3.935

6.  A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood.

Authors:  Stefan Seeber; Francesca Ros; Irmgard Thorey; Georg Tiefenthaler; Klaus Kaluza; Valeria Lifke; Jens André Alexander Fischer; Stefan Klostermann; Josef Endl; Erhard Kopetzki; Achal Pashine; Basile Siewe; Brigitte Kaluza; Josef Platzer; Sonja Offner
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 7.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857

8.  SEC Based Method for Size Determination of Immune Complexes of Therapeutic Antibodies in Animal Matrix.

Authors:  Marta Boysen; Laura Schlicksupp; Ingeborg Dreher; Ralf Loebbert; Mario Richter
Journal:  J Immunol Res       Date:  2016-07-31       Impact factor: 4.818

9.  Development and characterization of an anti-rituximab monoclonal antibody panel.

Authors:  Minoru Tada; Takuo Suzuki; Akiko Ishii-Watabe
Journal:  MAbs       Date:  2018-01-29       Impact factor: 5.857

10.  IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF.

Authors:  François Ehrenmann; Quentin Kaas; Marie-Paule Lefranc
Journal:  Nucleic Acids Res       Date:  2009-11-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.